

Smruthi Organics Ltd

Market Cap.	52 Week H/L	CMP	Target Price
Rs. 188 Cr.	Rs. 219/117	Rs. 164	Rs. 213

PHARMA

Smruthi Organics Ltd has recently announced its performance for the quarter ended March 31, 2024 and financial year ended FY24. Following are the key financial highlights:

Particulars	Q4FY24	Q4FY23	YoY	Q3FY24	QoQ
Net Sales	39.71	36.83	7.8%	23.48	69.1%
EBITDA	4.10	2.29	79.0%	(1.12)	N.A.
EBITDA Margin	10.4%	6.2%	420 Bps	N.A.	N.A.
Profit before Tax	2.18	0.80	172.5%	(2.94)	N.A.
Profit (loss) after Tax	1.52	0.69	120.3%	(2.29)	N.A.
PAT Margin	3.8%	1.8%	200 Bps	N.A.	N.A.
EPS	1.33	1.07	24.3%	(2.00)	N.A.

Highlights from the Quarter (Q4FY24):

Smruthi Organics Ltd (SOL) reported a comparatively stronger quarterly revenue of Rs. 39.71 cr for Q4FY24, up 7.8% YoY and 69.1% on a QoQ basis. The quantitative performance of the company reported all-round improvement as compared to the previous quarter. This is primarily attributed to the process of backward integration steadily gaining traction, thereby enhancing margins. The company reported a much improved net profit of Rs. 1.52 cr for the quarter, turning positive from the previous quarter, and up 120% YoY.

However, on a full year basis, Smruthi Organics Ltd posted slightly weaker results, falling at revenue levels. As raw material price pressure slowly eased through the year, EDITDA margins drastically improved to 9.4% from 7% in FY23. Additionally, the ongoing backward integration as well as the implementation of various cost saving measures has also contributed to improved margins at the end of the financial year.

Smruthi Organics Ltd has filed Drug Master Files in several PIC/S (Pharmaceutical Inspection Co-operation Scheme) signatory countries in order to gain market access in those countries and export their products. The company is focused more on regulated markets such as EU, Brazil, South Korea, and Europe. During the year, SOL obtained approval from the Korean FDA for the marketing of their Telmisaratan (used to treat high blood pressure) product in the Korean market, which the management believes to be a significant milestone. The company strives to gain further access in various other PIC/S signatory countries, which will help them multiply their revenue in the coming years.

With respect to the FDF division, SOL launched 2 new brands namely Enerlin (multivitamins) and Solsita (anti-diabetes) in FY23. In FY24, the company has worked towards the launch of various new brands, and intends to introduce new innovative brands going forward across geographies.

STOCK DATA

BUY

Reuters Code Bloomberg Co	de	SMOLf.BO SORG IN
BSE Code NSE Symbol		540686 -
Face Value		Rs.10
Shares Outstanding		1.1 Cr.
Avg. Daily Volume (6m)		11,308 Shares
Price Performa	ance (%)	
1M	3M	6M
5	(5)	(8)
200 da	ys EMA F	Rs.165

SHARE HOLDING (%)

Promoters	63.8
FII	-
FI / MF	1.4
Govt. Holding	-
Bodies Corporate	3.5
Public & Others	31.2

RESEARCH ASSOCIATE

Yash Dalal | +91 22 4093 4077 yash.dalal@sushilfinance.com

SALES:

Devang Shah | +91 22 4093 6060/61 devang.shah@sushilfinance.com

OUTLOOK AND VALUATION

Smruthi Organics Ltd posted a relatively stronger quarter in terms of revenue numbers as well as margins. As backward integration and FDF expansion continues to be a major focus for the company, as well as the continual focus to increase presence in the PIC/S signatory countries sustains, we can expect revenues as well as margins to improve in the coming quarters. We expect FY26E revenue at Rs.175.7 cr, EBITDA of Rs.22.5 cr at an EBITDA margin of 12.8% and PAT of Rs.10.1 cr. We estimate FY26E EPS at Rs.8.9, and assign a PE multiple of 24x, maintaining the target price of Rs.213. We keep our BUY Rating for Smruthi Organics Ltd over an investment horizon of 18-24 months.



KEY FINANCIALS

Y/E Mar	Revenue	EBITDA	EBITDA	PAT	NPM	A-EPS	P/E	P/S	P/BV
T/E IVIAI	(Rs. Cr)	(Rs. Cr)	Margin (%)	(Rs. Cr)	(%)	(Rs.)	(x)	(x)	(x)
FY23	141.1	9.9	7.0%	4.1	2.9%	3.6	45.3	19.5	2.8
FY24	127.7	12.0	9.4%	3.6	2.8%	3.1	52.5	16.0	2.7
FY25 E	154.1	16.2	10.5%	5.7	3.7%	4.9	33.2	11.9	2.6
FY26 E	175.7	22.5	12.8%	10.1	5.8%	8.9	18.5	8.6	2.3



Earlier Recommendation

Date	Report Type	Reco	Price (Rs.)	Target (Rs.)	
23-Dec-22	Initiating Coverage	Buy	157	213	

May 9, 2024 2



PROFIT & LOSS STATEMENT

(Rs.Cr.)

Y/E Mar.	FY23	FY24	FY25E	FY26E
Revenue	141	128	154	176
Raw Material Cost	91	72	92	101
Employee Cost	16	17	17	19
Other Expenses	24	26	29	33
EBITDA	10	12	16	22
EBITDA Margin (%)	7.0%	9.4%	10.5%	12.8%
Depreciation	5	6	5	5
EBIT	5	6	11	17
EBIT Margin (%)	3.8%	5.0%	7.2%	9.8%
Finance Costs	1	1	4	4
Other Income	0	0	0	0
Profit before Tax	5	5	8	14
Tax Expense	0	1	2	3
Adjusted PAT	4	4	6	10
Net Margin (%)	2.9%	2.8%	3.7%	5.8%
Adjusted EPS	3.6	3.1	4.9	8.9

BALANCE SHEET

(Rs.Cr.)

Y/E Mar.	FY23	FY24	FY25E	FY26E
PP&E	37	40	41	43
Right of Use Assets	-	0	0	0
Capital WIP	2	1	1	1
Other Non-Current	1	2	2	2
Goodwill	-	-	-	-
Inventories	24	30	33	37
Trade Receivables	37	41	44	48
Cash and Bank Balances	1	1	3	6
Other Current Assets	4	4	4	4
Total Assets	106	118	129	142
Equity Share Capital	11	11	11	11
Other equity	57	58	62	69
Non-Current trade payables	-	-	-	-
Borrowings	1	6	4	3
Other Non-Current Liabilities	1	1	1	1
Current lease liabilities	-	-	-	-
Trade Payables	25	29	35	40
Other Financial Liabilities	0	0	0	1
Current Borrowings	5	6	8	8
Other Current Tax Liab & Provisions	5	7	7	7
Total Liabilities	106	118	129	142

Source: Company, Sushil Finance Research

May 9, 2024 3



CASH FLOW STATEMENT

(Rs.Cr.)

Y/E Mar.	FY23	FY24	FY25E	FY26E
PBT	5	5	8	14
Depreciation	5	6	5	5
Interest	1	1	4	4
CFO before Working Cap chg	10	12	16	22
Chg in Inventories	(4)	(6)	(3)	(4)
Chg in Trade Receivables	(8)	(4)	(3)	(4)
Chg in Trade Payables	15	4	7	5
Chg in Current Assets &	_	_		
Liabilities		_		
Cash Flow from Operations	12	6	17	19
Interest Paid	(1)	(1)	(4)	(4)
Dividend Paid	(2)	(2)	(2)	(2)
Income Taxes Paid	(0)	(1)	(2)	(3)
Other Adjustments	(1)	7	1	0
Cash Flow from Financing	(5)	2	(7)	(9)
Capital Expenditure	(8)	(8)	(7)	(7)
Other Adjustments	2	0	(0)	(0)
Cash Flow from Investing	(6)	(8)	(7)	(7)
Opening Cash	(1)	0	1	3
Total Cash Flow	1	0	2	3
Closing Cash	0	1	3	6

FINANCIAL RATIO STATEMENT

Y/E Mar.	FY23	FY24	FY25E	FY26E
Growth (%)				
Revenue	5.4%	-9.5%	20.6%	14.0%
EBITDA	-47.9%	21.6%	34.8%	38.3%
Net Profit	-60.2%	-13.6%	58.0%	79.5%
Profitability (%)				
EBITDA Margin	7.0%	9.4%	10.5%	12.8%
Net Profit Margin	2.9%	2.8%	3.7%	5.8%
ROCE	7.2%	7.9%	13.2%	18.6%
ROE	6.1%	5.1%	7.7%	12.6%
Per Share Data (Rs.)				
EPS	3.6	3.1	4.9	8.9
BVPS	59.5	60.8	63.8	70.6
DPS	2.0	1.5	2.0	2.0
CEPS	7.6	8.1	9.4	13.5
Valuation (x)				
P/E	45.3	52.5	33.2	18.5
P/BV	2.8	2.7	2.6	2.3
EV/EBITDA	19.5	16.0	11.9	8.6
P/Sales	1.3	1.5	1.2	1.1
<u>Turnover</u>				
Inventory days	62	85	130	134
Debtor days	96	117	105	100
Creditor days	64	82	84	84
Gearing (x)				
D/E	0.08	0.17	0.16	0.14

Source: Company, Sushil Finance Research

May 9, 2024



Rating Scale:

This is a guide to the rating system used by our Institutional Research Team. Our rating system comprises of three rating categories.

Total Expected Return Matrix (Rating and Return) BUY: Over 12% HOLD: -12% to 12% SELL: Below -12%

Disclaimer & Disclosures:

https://www.sushilfinance.com/Disclaimer/research

https://www.sushilfinance.com/InvestorGrievances/researchanalystinvestorgrievancecell

This report has been furnished to you for your general information only and should not be reproduced, re-circulated, published in any media, website or otherwise, in any form or manner, in part or as a whole, without the express consent in writing of Sushil Financial Services Private Limited. This Research Report is meant solely for use by the original recipient to whom it is sent and is not for circulation. Any unauthorized use, disclosure or public dissemination or copying of information (either whole or partial) contained herein is prohibited.

This Report does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. The recommendations, if any, made herein are expression of views and/or opinions and should not be deemed or construed to be neither advice/offer for the purpose of purchase or sale of any securities mentioned herein. Past performance is not a guide for future performance, future returns are not guaranteed. Opinions expressed herein are subject to change without notice. Investor should rely on information/data arising out of their own investigations. The Sushil Equity Universe is marked as # and the fundamental reports are marked as ##.

Investors are advised to seek independent professional advice and arrive at an informed trading/investment decision before executing any trades or making any investments. The price and value of the investments referred to in this material and the income from them may go down as well as up, and investor may realize losses on any investments. This Report has been prepared on the basis of publicly available information, internally developed data and other sources believed by us to be reliable. A graph of daily closing prices of securities is available at www.nseindia.com, <a hre

Sushil Financial Services Private Limited (SFSPL) and its connected companies, and their respective Directors, Officers and employees or their relative, may have a long or short position in the subject companies mentioned in the report and it may not be construed as potential conflict of interest with respect to any recommendation and related information and opinions. Reports based on technical and derivative analysis centre on studying charts company's price movement, outstanding positions and trading volume, as opposed to focusing on a company's fundamentals and, as such, may not match with a report on a company's fundamental analysis. SFPSL has different business segments/Divisions with independent research and maintains arm's length distance catering to different set of customers having various objectives, risk profiles, investment horizon, etc. and therefore may at times have different contrary views on stocks sector and markets. Research Report may differ between SFSPL's RAs on account of differences in research methodology, personal judgment and difference in time horizons for which recommendations are made. User should keep this risk in mind and not hol-SFSPL, its employees and associates responsible for any losses, damages of any type whatsoever.

This Report is not intended to be a complete statement or summary of the securities, market or developments referred to in this document. SFSPL or its affiliates or employees are under no obligation to update the information. SFSPL or its affiliates or employees shall not be in any way responsible and liable for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report.

SFSPL or its affiliates and/or its employees/its associates or his relative does not have financial interest in the subject companies. SFSPL or its affiliates and/ or its employees/its associates or his relative may or may not have beneficial ownership of one per cent or more securities of the subject company, at the end of the month immediately preceding the date of publication of the research report. SFSPL/its Associates/ Research Analyst have not received any compensation from the subject company in the past twelve months. Further the subject company is/was not a client during twelve months preceding the date of distribution of the research report and the types of services provided. SFSPL or its research analyst has not served as an officer, director or employee of the subject company. SFSPL or its affiliates and/or its research analysts have not been engaged in market making activity for the subject company. SFSPL or its associates or its Research Analyst have not received any compensation or other benefits from the subject companies or third party in connection with the research report. SFSPL/its Associates/ Research Analyst/ his Relatives not have any other material conflict of interest at the time of publication of the research report.

SFSPL/its Associates/ Research Analyst have not managed or co-managed public offering of securities, have not received compensation for investment banking or merchant banking or brokerage services, have not received any compensation for product or services other than investment banking or merchant banking or brokerage services from the subject companies in the last twelve months. There is no material disciplinary action that been taken by any regulatory authority impacting equity research analysis activities.

Research Disclaimer: Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Sushil Financial Services Private Limited

Member: BSE / NSE - SEBI Regn. No. INZ000165135 Research Analyst – SEBI Registration No. INH000000867

Compliance officer / Grievance Officer :

Mr. Suresh Nemani – Phone : +91 22-40935000 |
Email : suresh.nemani@sushilfinance.com |
Grievance Email - compliance@sushilfinance.com
Regd. Office : 12, Homji Street, Fort, Mumbai 400 001.
Phone: +91 22 40936000 Fax: +91 22 22665758 |

Email: info@sushilfinance.com

Analyst Stock OwnershipNo	Yes
Stock Recommended to Clients	Yes
Remuneration/Benefits received from company in 12 months	No
Merchant Banking Market Making activities / projects	No
Sushil Financial Services Pvt. Ltd and Group Companies Holding	No
Sushil Financial Services Pvt. Ltd and Group Directors Holding	Yes
Broking Relationship with the company covered	No

May 9, 2024